N/A N=88 Psychosocial Treatment for Attention Deficit Hyperactivity Disorder in Adults
Attention Deficit Disorder With Hyperactivity
Primary: Inattention Subscale — -13.71; -16.18 units on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=107 Phenethyl Isothiocyanate in Preventing Lung Cancer in Smokers
Lung Cancer · Tobacco Use Disorder
Primary: Urinary Levels of Biomarkers of NNK Metabolism — 42.8; 0.36; 0.28; 49.7 pmol/mg creatinine
Phase 2 N=69 Essentiality of INH in TB Therapy
Tuberculosis
Primary: Daily Decrease in log10 Transformed Colony-forming Unit (CFU) Counts Per ml Sputum From Baseline (Study Treatment Initiation) to Day 14 — 0.134; 0.096; 0.136; 0.119…
Phase 3 N=87 Sulfasalazine in Preventing Acute Diarrhea in Patients With Cancer Who Are Undergoing Pelvic Radiation Therapy
Diarrhea · Gastrointestinal Complications · Unspecified Adult Solid Tumor, Protocol Specific
Primary: Maximum Severity of Diarrhea Toxicity as Measured by the CTCAE v4.0 During and After Radiotherapy (RT) — 10; 10; 13; 15 Participants — p=0.41
Phase 1 N=46 A Study of MK-7145 Compared to Placebo and Hydrochlorothiazide for Lowering Blood Pressure in Male Participants With Hypertension (MK-7145-009)
Hypertension
Primary: Change From Baseline in Time-weighted Average Over 24 Hours Post Dose (TWA [0-24]) in Systolic Blood Pressure (SBP) — -9.5; -10.2; -4.8; -2.8 mmHg
N/A N=79 Use of BIP-Needles in Rheumatologic Injections
Intra-articular Injections
Primary: True Positive Detection of Synovial Fluid Marked in Case Report Form — 86 percentage of injected joints
Phase 2 N=30 Tofacitnib for the Treatment of Alopecia Areata and Variants
Alopecia Areata (AA) · Alopecia Totalis (AT) · Alopecia Universalis (AU)
Primary: Mean Change in Severity of Alopecia Tool (SALT) Score — 22.8 percent change in SALT score
Phase 2 N=9 Oxytocin Treatment of Alcohol Dependence
Alcohol Withdrawal · Alcohol Dependence
Primary: Change in Clinical Institute Withdrawal Assessment for Alcohol (CIWA) Score — -2.76; 1.01 units on a scale
N/A N=80 In Clinic Evaluation of the PLGM Feature
Type 1 Diabetes
Primary: Serious Adverse Events (SAE) — 0 Participants
Phase 4 N=40 Duration of Antibiotic Therapy as Part of Maximal Medical Therapy for Chronic Rhinosinusitis
Sinusitis
Primary: Number of Patients Recommended for Sinus Surgery After 3 Weeks of Antibiotic Therapy — 7; 8; 0; 6 Participants
Phase 3 N=108 Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Promyelocytic Leukemia
Childhood Acute Promyelocytic Leukemia With PML-RARA · Myeloid Neoplasm
Primary: Event-free Survival (EFS) — 95.4; 82.9 Percentage of participants
N/A N=615 Individual Counseling and/or Computer-Based Counseling in Helping Healthy Women Adopt a Cancer Prevention Diet
Unspecified Adult Solid Tumor, Protocol Specific
Primary: Change in Fruit, Vegetable Consumption as Measured by Food Frequency Questionnaire at 3 Months — 2.7272727; 2.9758065; 2.7330645; 0.4720000 number of servings per day
Phase 4 N=6 Safety And Efficacy Of Sildenafil In Children With Pulmonary Arterial Hypertension
Pulmonary Arterial Hypertension · Hypertension, Pulmonary
Primary: Change From Baseline in Pulmonary Vascular Resistance Index (PVRI) at Week 16 — 18.567; -4.113 wood units*meter^2
Phase 3 N=8 The Impact of Free Fatty Acid (FFA-) Suppression on Myocardial Lipids and Function in Patients With Type 2 Diabetes
Type 2 Diabetes
Primary: MYCL — 0.54; 0.44; 0.35; 0.36 percentage of water signal
N/A N=172 The Angel® Catheter Pivotal Clinical Trial
Pulmonary Embolism · Deep Vein Thrombosis · Venous Thromboembolism
Primary: Freedom From Clinically Significant PE or Fatal PE During Treatment Period — 163 Participants